<div id="readability-page-1"><p>In a report released yesterday, Benjamin Burnett from Wells Fargo maintained a Hold rating on United Therapeutics, with a price target of <span id="expert-recommendation-target">$423.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Burnett covers the Healthcare sector, focusing on stocks such as Alkermes, Xenon, and MannKind. According to TipRanks, Burnett has an average return of <span>-3.0%</span> and a 40.50% success rate on recommended stocks. </p> <p>The word on The Street in general, suggests a Moderate Buy analyst consensus rating for United Therapeutics with a $521.25 average price target.</p></div>

UTHR

<p>Wells Fargo analyst Benjamin Burnett reaffirmed a Hold rating on United Therapeutics with a $423 price target. Despite Burnett's average return of -3.0% and a 40.50% success rate, the general analyst consensus is a Moderate Buy with a $521.25 average price target.</p>

Wells Fargo Reaffirms Their Hold Rating on United Therapeutics (UTHR)